1982 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Vanna Chiarion Sileni is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 16 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Cholecystectomy during esophagectomy is safe but unnecessary

Cavallin, F., Scarpa, M., Cagol, M., Alfieri, R., Ruol, A., Chiarion Sileni, V., Rugge, M., Ancona, E. & Castoro, C., Feb 2020, In : Acta Chirurgica Belgica. 120, 1, p. 35-41 7 p.

Research output: Contribution to journalArticle

  • Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial

    Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., Lebbe, C., Ferraresi, V., Smylie, M., Weber, J. S., Maio, M., Hosein, F., de Pril, V., Kicinski, M., Suciu, S. & Testori, A., Sep 2019, In : European Journal of Cancer. 119, p. 1-10 10 p.

    Research output: Contribution to journalArticle

  • Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management

    Gogas, H. J., Flaherty, K. T., Dummer, R., Ascierto, P. A., Arance, A., Mandala, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsova, I., Gutzmer, R., Sileni, V. C., Dutriaux, C., de Groot, J. W. B., Yamazaki, N., Loquai, C., Gollerkeri, A., Pickard, M. D. & Robert, C., Sep 2019, In : European Journal of Cancer. 119, p. 97-106 10 p.

    Research output: Contribution to journalArticle

  • An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

    Larkin, J., Brown, M. P., Arance, A. M., Hauschild, A., Queirolo, P., Vecchio, M. D., Ascierto, P. A., Krajsová, I., Schachter, J., Neyns, B., Garbe, C., Sileni, V. C., Mandalà, M., Gogas, H., Espinosa, E., Hospers, G., Lorigan, P., Nyakas, M., Guminski, A., Liszkay, G. & 5 others, Rutkowski, P., Miller, W., Donica, M., Makrutzki, M. & Blank, C., Jan 2019, In : European Journal of Cancer. 107, p. 175-185 11 p.

    Research output: Contribution to journalArticle

  • An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

    Larkin, J., Brown, M. P., Arance, A. M., Hauschild, A., Queirolo, P., Vecchio, M. D., Ascierto, P. A., Krajsová, I., Schachter, J., Neyns, B., Garbe, C., Sileni, V. C., Mandalà, M., Gogas, H., Espinosa, E., Hospers, G., Lorigan, P., Nyakas, M., Guminski, A., Liszkay, G. & 5 others, Rutkowski, P., Miller, W., Donica, M., Makrutzki, M. & Blank, C., Jan 1 2019, In : European Journal of Cancer. 107, p. 175-185 11 p.

    Research output: Contribution to journalArticle